Ganesh Veerappan, MD
Gastroenterology · Akron, OHNPI 1780650895
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,263 of the $188,245 with a category attached, or 84.1%. 32 manufacturers reported payments, led by AbbVie at 39.5% of the total. 2025 is the largest year on record at $74,610, 9.7 times the $7,725 reported in 2019. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $428.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$74K
- Johnson & Johnson$70K
- Pfizer$39K
- Sanofi$2K
- Phathom Pharmaceuticals, Inc.$327
- Bristol Myers Squibb$305
- plus $2K from 26 others
Across 68 payments — averaging $2448.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$126K
- Boehringer Ingelheim International GmbH$20K
- Chugai Pharmaceutical Co., Ltd.$15K
- Caris MPI, Inc.$4K
- Eli Lilly$2K
What the payments were for
- Consulting fees$7,8914%
- Speaking & faculty fees$158,26384%
- Travel & lodging$10,9856%
- Food & beverage$10,9226%
- Education$1840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 178 | $74,344 |
| Johnson & Johnson | 75 | $70,385 |
| Pfizer | 75 | $38,907 |
| Sanofi | 4 | $2,041 |
| Phathom Pharmaceuticals, Inc. | 6 | $327 |
| Bristol Myers Squibb | 22 | $305 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $302 |
| Shire North American Group Inc | 1 | $200 |
| Madrigal Pharmaceuticals | 7 | $159 |
| Lilly USA, LLC | 6 | $150 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $122 |
| Ardelyx, Inc. | 6 | $121 |
| Merck | 7 | $114 |
| Novo Nordisk | 1 | $113 |
| QOL Medical, LLC | 5 | $100 |
| Intercept Pharmaceuticals, Inc. | 3 | $50 |
| Nestle Healthcare Nutrition Inc. | 3 | $44 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Gilead | 2 | $36 |
| Fresenius Kabi USA, LLC | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Organon | 1 | $27 |
| Boston Scientific | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Vivus LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Dentsply IH Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$188,245 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 24 | $529,430 |
| EntyvioVedolizumab | 14 | $126,847 |
| SkyriziRisankizumab-Rzaa | 11 | $111,403 |
| RinvoqUpadacitinib | 12 | $111,175 |
| XifaxanRifaximin | 12 | $35,870 |
| LinzessLinaclotide | 22 | $24,758 |
| Alosetron Hcl | 12 | $18,487 |
| Mesalamine | 27 | $17,372 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 61 | $9,615 |
| Mesalamine ErMesalamine | 15 | $8,424 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 84 | $5,902 |
| Sucralfate | 46 | $5,812 |
| Colestipol Hcl | 40 | $2,965 |
| Omeprazole | 219 | $2,409 |
| Balsalazide Disodium | 11 | $1,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi, Rinvoq, Linzess | $74,344 | $247,33645 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $302 | $126,84714 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $122 | $35,87012 claims |
| Braintree Laboratories, Inc.Sutab | $14 | $9,61561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Akron
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
- Stanley CohenCleveland$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.